Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer

Conclusion.The ORR and PFS in the weekly regimen were better than those in the biweekly schedule, although a statistical difference was not observed. The toxicity profile was generally mild for both regimens. The weekly CP regimen was suitable to be considered as an alternative to the current 3‐weekly regimen in NSCLC treatment.

Source: The Oncologist - November 12, 2019 Category: Cancer & Oncology Authors: Koichi Takayama, Masao Ichiki, Shoji Tokunaga, Koji Inoue, Masayuki Kawasaki, Junji Uchino, Yoichi Nakanishi Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research